On August 14, 2026, the clinical trial registry updated the status of a study involving semaglutide to completed. The trial, titled "Cardiac and Metabolic Effects of Semaglutide in Heart Failure With Preserved Ejection Fraction," is registered under identifier NCT05371496. It is listed as a Phase 4 study, indicating it was conducted after the compound's initial approval to gather further data in this patient population. Semaglutide is currently an approved compound.
The registry entry confirms the trial's completed status as of the update date but does not include posted results in this update. No outcome data, efficacy findings, or safety conclusions are included in this event. The trial focused on evaluating cardiac and metabolic effects of semaglutide specifically in patients with heart failure with preserved ejection fraction, according to the study title.
This update reflects only a change in trial status within the registry record. Readers should not interpret a completed status as confirmation of specific results, benefits, or risks associated with semaglutide in this context. Further information, if and when posted, would appear as a separate update to the same trial record.
For more background on this compound, see the linked compound overview.